Slide 1: Fourth Quarter 2017 Earnings Teleconference
Fourth Quarter 2017 Earnings Teleconference January 30, 2018
Slide 2: Introduction
Introduction Chuck Triano Senior Vice President, Investor Relations Fourth Quarter 2017 Earnings
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, in-line products and product candid
Slide 4: Opening Remarks
Opening Remarks Ian Read Chairman and Chief Executive Officer Fourth Quarter 2017 Earnings
Slide 5: CEO Perspectives
CEO Perspectives Pfizer Innovative Health had another strong year with 8% operational revenue growth Ibrance, Eliquis, Xeljanz, Chantix, Lyrica and Xtandi are all contributing to PIH growth Pfizer Essential Health, although revenues declined for the year, achieved operational revenue growth of
Slide 6: Financial Review
Financial Review Frank D’Amelio Executive Vice President & Chief Financial Officer Fourth Quarter 2017 Earnings
Slide 7: Income Statement Highlights
Income Statement Highlights ($ Millions, Except Per Share Amounts and Percentages) Fourth Quarter Full Year 2017 2016 Change 2017 2016 Change Revenues $13,703 $13,627 1% $52,546 $52,824 (1%) Reported Net Income(1) 12,274 775 * 21,308 7,215 * Reported Diluted EPS(1) 2.02 0.13 * 3.52 1.17 * Adjusted I
Slide 8: Impact of Foreign Exchange on Revenues and Select Adjusted Income Components
Impact of Foreign Exchange on Revenues and Select Adjusted Income(1) Components ($ Millions, Except Percentages) Favorable / (Unfavorable) Fourth Quarter 2017 2016 FX Impact Revenues $13,703 $13,627 $114 1% Adjusted Cost of Sales(1) 3,062 3,046 (81) (3%) COS as a Percentage of Revenues 22.3% 22.4% (
Slide 9: 2017 Financial Guidance
2017 Financial Guidance(1)(2) Guidance Results Revenues $52.4 to $53.1 billion $52.5 billion Adjusted Cost of Sales(3) as a Percentage of Revenues 20.0% to 20.5% 20.5% Adjusted SI&A Expenses(3) $14.0 to $14.5 billion $14.5 billion Adjusted R&D Expenses(3) $7.5 to $7.8 billion $7.6 billion Adjusted O
Slide 10: 2018 Financial Guidance
2018 Financial Guidance(1)(2) Revenues $53.5 to $55.5 billion Adjusted Cost of Sales(3) as a Percentage of Revenues 20.5% to 21.5% Adjusted SI&A Expenses(3) $14.0 to $15.0 billion Adjusted R&D Expenses(3) $7.4 to $7.9 billion Adjusted Other (Income) / Deductions(3) Approximately $400 million of inco
Slide 11: Key Takeaways
Key Takeaways Achieved solid Q4 2017 financial results, with 2% operational revenue growth, excluding revenues for Hospira Infusion Systems from the prior-year quarter, primarily driven by Eliquis globally and Xeljanz primarily in the U.S. Issued 2018 financial guidance, representing 4% revenue grow
Slide 12: Q&A Session
Fourth Quarter 2017 Earnings Teleconference Q&A Session January 30, 2018